Improved methanol-derived lovastatin production through enhancement of the biosynthetic pathway and intracellular lovastatin efflux in methylotrophic yeast

Abstract

Background

Methanol has attracted interest as a substrate for improvement of product titers and yields of bioprocesses, because methanol has a more reduced state than sugars do and can be renewably synthesized from abundant natural gas supplies. Our aim was to engineer methylotrophic Pichia pastoris to convert methanol into value-added lovastatin more productively.

Results

A strengthened biosynthetic pathway of lovastatin was constructed through the assembly of three modules with increasing module-specific antibiotic stress in the methylotrophic yeast P. pastoris. The resulting strain (P. p/LV_V#9) produced 287.5 ± 2.0 mg/L lovastatin in a 5-L bioreactor from methanol. The production was further improved by identification and overexpression of a statin pump protein, TapA, a membrane protein capable of lovastatin efflux out of the cell. A TapA-overexpressing strain, P. p/LV_V#9-TapA, produced 419.0 ± 9.5 mg/L lovastatin from methanol: 46% more than P. p/LV_V#9 did, and 520% more relative to the strain (P. p/LV_SC) with single-copy genes.

Conclusions

A methylotrophic yeast strain producing 419.0 ± 9.5 mg/L lovastatin was constructed by optimization of biosynthetic gene dosages and coexpression of a statin pump protein; these results proved that P. pastoris is a promising chassis organism for natural-product biosynthesis. A membrane protein, TapA was found to perform the function of exporting intracellular lovastatin and enhanced lovastatin production.

Keywords

Enhanced biosynthetic pathway / Lovastatin / Methanol / Pichia pastoris / Statin pump protein

References

[1] Ahmad M, Hirz M, Pichler H, Schwab H. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol, 2014, 98: 5301-5317.

[2] Barriuso J, Nguyen DT, Li JW, Roberts JN, MacNevin G, Chaytor JL, Marcus SL, Vederas JC, Ro DK. Double oxidation of the cyclic nonaketide dihydromonacolin L to monacolin J by a single cytochrome p450 monooxygenase, lovA. J Am Chem Soc, 2011, 133: 8078-8081.

[3] Bennett RK, Steinberg LM, Chen W, Papoutsakis ET. Engineering the bioconversion of methane and methanol to fuels and chemicals in native and synthetic methylotrophs. Curr Opin Biotechnol, 2018, 50: 81-93.

[4] Billingsley JM, DeNicola AB, Tang Y. Technology development for natural product biosynthesis in Saccharomyces cerevisiae. Curr Opin Biotechnol, 2016, 42: 74-83.

[5] Campbell CD, Vederas JC. Biosynthesis of lovastatin and related metabolites formed by fungal iterative pks enzymes. Biopolymers, 2010, 93: 755-763.

[6] Cregg JM, Cereghino JL, Shi J, Higgins DR. Recombinant protein expression in Pichia pastoris. Mol Biotechnol, 2000, 16: 23-52.

[7] Galanie S, Thodey K, Trenchard IJ, Interrante MF, Smolke CD. Complete biosynthesis of opioids in yeast. Science, 2015, 349: 1095-1100.

[8] Huang X, Liang Y, Yang Y, Lu X. Single-step production of the simvastatin precursor monacolin J by engineering of an industrial strain of Aspergillus terreus. Metab Eng, 2017, 42: 109-114.

[9] Kennedy J, Auclair K, Kendrew SG, Park C, Vederas JC, Hutchinson CR. Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. Science, 1999, 284: 1368-1372.

[10] Ley A, Coumou HC, Frandsen RJN. Heterologous expression of MlcE in Saccharomyces cerevisiae provides resistance to natural and semi-synthetic statins. Metab Eng Commun, 2015, 2: 117-123.

[11] Liu Y, Tu X, Xu Q, Bai C, Kong C, Liu Q, Peng Q, Zhou X, Zhang Y, Cai M. Engineered monoculture and co-culture of methylotrophic yeast for de novo production of monacolin J and lovastatin from methanol. Metab Eng, 2018, 45: 189-199.

[12] Martín JF, Casqueiro J, Liras P. Secretion systems for secondary metabolites: how cells send out messages of intercellular communication. Curr Opin Microbiol, 2005, 8: 282-293.

[13] Price JV, Chen L, Whitaker WB, Papoutsakis E, Chen W. Scaffoldless engineered enzyme assembly for enhanced methanol utilization. Proc Natl Acad Sci USA, 2016, 113: 12691-12696.

[14] Räuchle K, Plass L, Wernicke HJ, Bertau M. Methanol for renewable energy storage and utilization. Energy Technol, 2016, 4: 193-200.

[15] Ro DK, Paradise EM, Ouellet M, Fisher KJ, . Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature, 2006, 440: 940-943.

[16] Schwarzhans JP, Luttermann T, Geier M, Kalinowski J, Friehs K. Towards systems metabolic engineering in Pichia pastoris. Biotechnol Adv, 2017, 35(6): 681-710.

[17] Singh SK, Pandey A. Emerging approaches in fermentative production of statins. Appl Biochem Biotechnol, 2013, 171(4): 927-938.

[18] Vogl T, Hartner FS, Glieder A. New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris. Curr Opin Biotechnol, 2013, 24: 1094-1101.

[19] Wang F, Lv X, Xie W, Zhou P, Zhu Y, Yao Z, Yang C, Yang X, Ye L, Yu H. Combining Gal4p-mediated expression enhancement and directed evolution of isoprene synthase to improve production in Saccharomyces cerevisiae. Metab Eng, 2017, 39: 257-266.

[20] Whitaker WB, Sandoval NR, Bennett RK, Fast AG, Papoutsakis ET. Synthetic methylotrophy: engineering the production of biofuels and chemicals based on the biology of aerobic methanol utilization. Curr Opin Biotechnol, 2015, 33: 165-175.

[21] Xie X, Watanabe K, Wojcicki WA, Wang CC, Tang Y. Biosynthesis of lovastatin analogs with a broadly specific acyltransferase. Chem Biol, 2006, 13: 1161-1169.

[22] Xu W, Chooi YH, Choi JW, Li S, Vederas JC, Da Silva NA, Tang Y. LovG: the thioesterase required for dihydromonacolin L release and lovastatin nonaketide synthase turnover in lovastatin biosynthesis. Angew Chem Int Ed, 2013, 52: 6472-6475.

[23] Yang Z, Zhang Z. Engineering strategies for enhanced production of protein and bio-products in Pichia pastoris: a review. Biotechnol Adv, 2017 in press)

Funding

Shanghai Science and Technology Innovation Action Plan(17JC1402400)